Public Employees Retirement Association of Colorado Sells 1,532 Shares of DexCom, Inc. (NASDAQ:DXCM)

Public Employees Retirement Association of Colorado decreased its stake in DexCom, Inc. (NASDAQ:DXCM) by 2.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 53,766 shares of the medical device company’s stock after selling 1,532 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in DexCom were worth $6,096,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Team Hewins LLC lifted its holdings in DexCom by 3.4% during the first quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock worth $354,000 after acquiring an additional 83 shares in the last quarter. Bleakley Financial Group LLC lifted its holdings in shares of DexCom by 1.3% during the 1st quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock valued at $951,000 after purchasing an additional 87 shares in the last quarter. Capital Insight Partners LLC increased its stake in DexCom by 2.5% during the 2nd quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock worth $418,000 after purchasing an additional 90 shares in the last quarter. Gulf International Bank UK Ltd increased its stake in DexCom by 0.3% during the 1st quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock worth $4,448,000 after purchasing an additional 93 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in DexCom by 10.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the medical device company’s stock worth $133,000 after buying an additional 98 shares during the period. Institutional investors own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on DXCM. Oppenheimer lowered their target price on DexCom from $150.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, July 26th. Stifel Nicolaus boosted their target price on DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, August 23rd. Wells Fargo & Company decreased their price target on shares of DexCom from $145.00 to $80.00 and set an “overweight” rating for the company in a research note on Friday, July 26th. Piper Sandler reissued an “overweight” rating and issued a $90.00 price objective on shares of DexCom in a research report on Monday, August 26th. Finally, Baird R W downgraded shares of DexCom from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 26th. Seven analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $112.25.

DexCom Stock Down 2.1 %

DXCM stock opened at $70.43 on Monday. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The business’s 50 day simple moving average is $78.19 and its 200 day simple moving average is $109.37. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. The firm has a market capitalization of $28.01 billion, a PE ratio of 45.44, a PEG ratio of 2.12 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.39 by $0.04. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The company’s quarterly revenue was up 15.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.34 earnings per share. As a group, research analysts anticipate that DexCom, Inc. will post 1.69 EPS for the current year.

Insider Activity at DexCom

In other news, EVP Michael Jon Brown sold 659 shares of the business’s stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $114.29, for a total transaction of $75,317.11. Following the completion of the sale, the executive vice president now owns 66,901 shares in the company, valued at $7,646,115.29. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Michael Jon Brown sold 659 shares of the business’s stock in a transaction dated Friday, June 28th. The shares were sold at an average price of $114.29, for a total value of $75,317.11. Following the completion of the transaction, the executive vice president now directly owns 66,901 shares of the company’s stock, valued at approximately $7,646,115.29. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 2,483 shares of company stock worth $201,708. Insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.